Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | P4HB | P07237 | 1/20 | 0.52 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.52 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479749 | 1.00 | TSHR (0.58) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL26364024 | 1.00 | TSHR (0.58) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL14478537 | 1.00 | TSHR (0.58) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL14353402 | 1.00 | TSHR (0.58) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL14353401 | 1.00 | TSHR (0.58) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL14477715 | 0.89 | TSHR (0.47) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL30578065 | 0.87 | LMNA (0.64) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL23480052 | 0.87 | LMNA (0.64) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL20633976 | 0.87 | P4HB (0.61) | TSHRCYP2D6THRBHSD17B10P4HB | |
| SCHEMBL7744449 | 0.87 | TSHR (0.59) | TSHRCYP2D6THRBHSD17B10P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, MPO | TSHR 4869/4885CYP2D6 2906/4885THRB 4653/4885 |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, MPO | TSHR 4869/4885CYP2D6 2906/4885THRB 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.